Testosterone Rx+, data-breach lawsuits, share price
Testosterone Rx+ (a compounded enclomiphene product) has formally launched and is the second growth engine after GLP-1. The data-breach lawsuits are short-term noise. The Q1 results on 11 May are the key window for validation.
Key insights
- Testosterone Rx+ is now live. The core ingredient is enclomiphene (clinically shown to double testosterone levels), combined with zinc, B6/B12 and L-arginine, taken as one pill a day, with tadalafil as an optional add-on.
- Enclomiphene stimulates the body's own testosterone production, does not suppress testicular function and preserves fertility, unlike traditional TRT
- HIMS data: testosterone rose in 95% of users, and 80% reached optimal levels within 60 days
- The launch coincides with the FDA's 30 Apr deadline on widening testosterone indications and is the product-side response
- Strategy: after GLP-1 weight loss, testosterone and men's health become the second growth engine, and the compounded-drug model (high margin) continues
Price action
On 1 May the shares closed at $27.17 (+3.19%), ending a 3-day losing streak. A rebound signal against the backdrop of the Testosterone Rx+ launch and fierce GLP-1 competition.
Q1 earnings preview
Q1 results come out on 11 May after the close, 9 days away. Subscriber data is the earliest window on whether the data breach has hurt user trust.
Risk flag
On 1 May several media outlets reported at least 2 class actions alleging weak data security and privacy protection, with users notified late, in April 2026. Assessment: short-term negative noise, with no formal regulatory involvement so far. Lawsuits over medical data breaches are common across the industry. The key is any later HIPAA penalty or sign of users leaving.
Sources (1)
- HIMS official release, media reports of 1 May, market data at the 1 May close
A brief is a lead for our research, not a verified conclusion or advice.